Abstract: The invention is a method for treating a heart failure patient with the steps of measuring the concentration of IGFBP2 in a blood, plasma or urine sample obtained from the heart failure patient and comparing the patient's IGFBP2 level to a threshold value derived from IGFBP2 measured in samples taken from a group of patients with heart failure selected from the group consisting of stage I, stage stage III and stage IV heart failure, according to New York Heart Association (NYHA) classification system. A patient with an IGFBP2 level that exceeds the threshold value is admitted or readmitted to a hospital and treated with at least one treatment selected from the group consisting of administration of a beta-blocker, an angiotensin-converting enzyme inhibitor, an angiotensin receptor blocker, an aldosterone antagonist, an implantable cardiac defibrillator, a cardiac resynchronization therapy, an implantable left ventricular assist device and a heart transplant.

Abstract: Disclosed herein is a method for classifying a patient at risk for heart failure, wherein the method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from the patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the concentration of IGFBP2 in samples from patients who are at particular stages of heart failure and/or to a control value derived from the concentration of IGFBP2 in blood samples from healthy patients.

Abstract: The invention relates to a method for classifying a patient at risk for heart failure, wherein said method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from said patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the concentration of IGFBP2 in samples from patients who are at particular stages of heart failure and/or to a control value derived from the concentration of IGFBP2 in blood samples from healthy patients.

Abstract: The invention relates to a method for establishing if a heart failure patient is susceptible to be hospitalized and/or rehospitalized, wherein said method comprises measuring the concentration of IGFBP2 in a sample obtained from said heart failure patient.

Abstract: The invention relates to a method for classifying a patient at risk for heart failure, wherein said method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from said patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the concentration of IGFBP2 in samples from patients who are at particular stages of heart failure and/or to a control value derived from the concentration of IGFBP2 in blood samples from healthy patients.

Abstract: The invention relates a method for diagnosing asymptomatic left ventricular systolic dysfunction in a subject comprising the step a) of: —measuring the level of expression of the genes FECH, TMEM79, FBXW7, NGFB, ALK, UBN1 and SLC43A2 in a biological sample of said subject; or—measuring the level of expression of at least one gene selected from the group consisting of FECH, TMEM79, FBXW7, NGFB, ALK, UBN1 and SLC43A2 in a biological sample of said subject.